Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Receivables (2019 - 2025)

Historic Receivables for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $12.7 million.

  • Biodesix's Receivables rose 5771.53% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 5771.53%. This contributed to the annual value of $8.6 million for FY2024, which is 1203.28% up from last year.
  • Biodesix's Receivables amounted to $12.7 million in Q3 2025, which was up 5771.53% from $7.5 million recorded in Q2 2025.
  • Biodesix's 5-year Receivables high stood at $18.4 million for Q1 2021, and its period low was $2.8 million during Q3 2021.
  • In the last 5 years, Biodesix's Receivables had a median value of $5.8 million in 2023 and averaged $7.1 million.
  • In the last 5 years, Biodesix's Receivables tumbled by 7945.23% in 2022 and then soared by 14588.49% in 2024.
  • Quarter analysis of 5 years shows Biodesix's Receivables stood at $3.7 million in 2021, then skyrocketed by 38.54% to $5.1 million in 2022, then skyrocketed by 51.61% to $7.7 million in 2023, then increased by 12.03% to $8.6 million in 2024, then soared by 47.32% to $12.7 million in 2025.
  • Its Receivables stands at $12.7 million for Q3 2025, versus $7.5 million for Q2 2025 and $7.6 million for Q1 2025.